Roflumilast increases bacterial load and dissemination in a model of pseudomononas aeruginosa airway infection

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 1, 2016, Pages 66-72

  Kasetty, Gopinath ^a   Papareddy, Praveen ^a   Bhongir, Ravi K V ^a   Egesten, Arne ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CHEMOKINE; CYCLOPROPANE DERIVATIVE; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFLUMILAST;

ANIMAL; BACTERIAL COUNT; BACTERIAL LOAD; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOLOGY; DRUG EFFECTS; FEMALE; LEUKOCYTE COUNT; LUNG; METABOLISM; MICROBIOLOGY; MOUSE; NEUTROPHIL; PATHOLOGY; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION;

AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL LOAD; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES; COLONY COUNT, MICROBIAL; CYCLOPROPANES; CYTOKINES; FEMALE; LEUKOCYTE COUNT; LUNG; MICE; MICE, INBRED BALB C; NEUTROPHILS; PSEUDOMONAS INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 84962524526     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.229641     Document Type: Article

References (31)

1. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, and Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196-204.
2. Buenestado A, Chaumais MC, Grassin-Delyle S, Risse PA, Naline E, Longchampt E, Tenor H, and Devillier P (2013) Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-a and chemokine production by human lung parenchyma. PLoS One 8:e74640.
3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, and Vestbo J; TORCH investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789.
4. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, and Martinez FJ; M2-124 and M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694.
5. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, and Rabe KF; M2-127 and M2-128 study groups (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695-703.
6. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbröker D, Bethke TD, Hiemstra PS, and Rabe KF (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62:1081-1087.
7. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
8. Houslay MD, Baillie GS, and Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100:950-966.
9. Inghammar M, Engström G, Ljungberg B, Löfdahl CG, Roth A, and Egesten A (2014) Increased incidence of invasive bacterial disease in chronic obstructive pulmonary disease compared to the general population-a population based cohort study. BMC Infect Dis 14:163.
10. Jacob C, Szilagyi C, Allen JM, Bertrand C, and Lagente V (2004) Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism. Br J Pharmacol 143:257-268.
11. Jones NA, Boswell-Smith V, Lever R, and Page CP (2005) The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18:93-101.
12. Konrad FM, Bury A, Schick MA, Ngamsri KC, and Reutershan J (2015) The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. PLoS One 10:e0121725.
13. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, and Cheon HG (2005) Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun. NH2-terminal kinase activation. J Pharmacol Exp Ther 315:1188-1195.
14. Le Quément C, Guénon I, Gillon JY, Valença S, Cayron-Elizondo V, Lagente V, and Boichot E (2008) The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 154:1206-1215.
15. Martorana PA, Beume R, Lucattelli M, Wollin L, and Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848-853.
16. McCluskie K, Klein U, Linnevers C, Ji YH, Yang A, Husfeld C, and Thomas GR (2006) Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J Pharmacol Exp Ther 319:468-476.
17. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, and Sethi S (2008) Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:853-860.
18. Page CP and Spina D (2011) Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handbook Exp Pharmacol 204:391-414.
19. Page CP and Spina D (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12:275-286.
20. Pittman K and Kubes P (2013) Damage-associated molecular patterns control neutrophil recruitment. J Innate Immun 5:315-323.
21. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, and Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 12:18.
22. Sethi S and Murphy TF (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355-2365.
23. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, and Ochando R (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925-931.
24. Strieter RM, Belperio JA, and Keane MP (2002) Cytokines in innate host defense in the lung. J Clin Invest 109:699-705.
25. Suzuki O, Goto T, Yoshino T, Nakamura S, and Maeda H (2015) The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor. Acta Pharm 65:191-197.
26. Suzuki O, Mizukami K, Etori M, Sogawa Y, Takagi N, Tsuchida H, Morimoto K, Goto T, Yoshino T, and Mikkaichi T, et al. (2013) Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice. J Pharmacol Sci 123:219-226.
27. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, and Investigators US; UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554.
28. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, and Puhan MA (2012) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12: CD010257.
29. Walters JA, Gibson PG, Wood-Baker R, Hannay M, and Walters EH (2009) Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (1): CD001288.
30. Wan WY, Morris A, Kinnear G, Pearce W, Mok J, Wyss D, and Stevenson CS (2010) Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation. Respir Res 11:126.
31. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, and Wedzicha JA (2003) Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1090-1095.